Optimizing the Role of the Pharmacist in LAI Administration During COVID-19
In recent years, overwhelming evidence suggests that LAIs may improve adherence, reduce relapse and hospitalizations, lessen the risk of treatment failure, and decrease mortality. Also, much evidence suggests the use of these treatments should no longer be reserved for last line, but offered at an earlier place in the illness. Moreover, new agents have arrived on the market which can be dosed without oral overlap, paving the way to less burdensome initiation strategies. Join Drs. Les Citrome and Megan Ehret for this on-demand online activity, exploring the important role of LAIs and the critical part pharmacists have to play in ensuring continuity of care for patients treated with LAIs.
This activity is supported by an educational grant from Alkermes.
This activity has been developed and accredited by Creative Educational Concepts, Inc. in partnership with the College of Psychiatric and Neurologic Pharmacists (CPNP).
Physicians, pharmacists, nurse practitioners, and nurses treating patients with LAIs in the time of COVID-19.
- Discuss the role and function of the pharmacist in administering LAI medications, detailing when pharmacists can be optimized in the treatment of patients with schizophrenia during COVID-19.
- Examine the expanded role pharmacists can play in administering LAI medications, beyond the public health emergency of COVID-19.
Leslie Citrome, MD, MPH
Clinical Professor, Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York
Dr. Citrome is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York, and has a private practice in Pomona, New York. He also is a member of the Board of Directors of the American Society of Clinical Psychopharmacology. Dr. Citrome spent nearly two decades as a researcher in psychopharmacological treatment of severe mental disorders, including the management of treatment-refractory schizophrenia, and the management of aggressive and violent behavior.
Dr. Citrome is the Editor-in-Chief of the International Journal of Clinical Practice, and is the author or co-author of more than 400 published research reports, reviews, book chapters, and books in the biomedical literature. He has lectured extensively throughout the United States, Canada, Europe, and Asia.
Megan J. Ehret, PharmD, MS, BCPP
Department of Pharmacy Practice and Science
University of Maryland, School of Pharmacy
Dr. Ehret is a graduate of the University of Toledo where she completed her BS and PharmD degrees, and she went on to complete a Psychiatric Pharmacy Residency at the Louis Stokes VAMC, under the direction of Matthew Fuller. She then completed a Psychopharmacology and Pharmacogenomics Fellowship at Nova Southeastern University, under the direction of Gary Levin. She is the current Past-President for the College of Psychiatric and Neurologic Pharmacists Association. Her full-time role is an Associate Professor at the University of Maryland School of Pharmacy with a practice site at The University of Maryland Mid Town Campus. She is currently Chair of the Student Affairs Committee. Additionally, she also has the privilege of working with the State of Maryland Medicaid Program in evaluating antipsychotic use in the state Dr. Ehret has numerous publications and book chapters describing psychotropic medication adherence and the role of pharmacogenomics in medication selection. Her current interests include psychotropic medication adherence and the advancement of the psychiatric pharmacist in practice.
Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Leslie Citrome, MD, MPH–has disclosed that he is a consultant for Acadia, Alkermes, Allergan, Avanir, BioXcel, Eisai, Impel, Indivior, Intra-Cellular Therapies, Janssen, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva, and Vanda. He receives royalties from Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics. He is also a member of the speakers’ bureau for Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, and Teva.Susan Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.
Steve Stoner, PharmD, BCPP–has disclosed that he is on the speakers’ bureau for Neurocrine.
Leslie Citrome, MD, MPH–has disclosed that he is a consultant for Acadia, Alkermes, Allergan, Avanir, BioXcel, Eisai, Impel, Indivior, Intra-Cellular Therapies, Janssen, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva, and Vanda. He receives royalties from Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics. He is also a member of the speakers’ bureau for Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, and Teva.
Megan J. Ehret, PharmD, MS, BCPP––has no relevant financial relationships to disclose in relation to the content of this activity.
Andrew Cutler, MD-has disclosed that he is a consultant for Alkermes, IntraCellular Therapies, Janssen, Lundbeck, Otsuka, and Sunovion; he receives grant/research support from Alkermes IntraCellular Therapies Janssen, Lundbeck, Otsuka, and Sunovion. He also is a member of the speakers’ bureau for Alkermes, IntraCellular Therapies, Janssen, Lundbeck, Otsuka, and Sunovion.
Deanna Kelly, PharmD, BCPP–has disclosed that she is consultant for Alkermes.
Amanda Simonton, ARNP–has disclosed that she is on a Medscape Education Steering Committee that is supported by grant money from Alkermes.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medicine (ACCME): CEC designates this live educational activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners (AANP): This activity is approved for 0.5 contact hour(s) of continuing education (which includes 0.25 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20084426. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Nursing (ANCC): This activity is designated for 0.50 contact hours.
Upon completion of the activity, statements of credit for physicians, physician assistants, and nurses will be issued automatically.
- 0.50 AANP Contact Hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation